(LLY) Eli Lilly - Ratings and Ratios
Insulin, Diabetes, Oncology, Immunology, Neuroscience
LLY EPS (Earnings per Share)
LLY Revenue
Description: LLY Eli Lilly
Eli Lilly & Co. (NYSE: LLY) is a global pharmaceutical firm headquartered in Indianapolis, Indiana, that discovers, develops, and markets prescription medicines across the United States, Europe, China, Japan, and other international markets.
The company’s product slate is anchored by a broad diabetes franchise-including Basaglar, Humalog (U-100, U-200, Mix 75/25, Mix 50/50), Humulin (R, N, 70/30, U-500) and the newer agents Jardiance, Mounjaro, and Trulicity-as well as the obesity treatment Zepbound. In oncology, Lilly sells Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Additional therapeutic areas cover inflammatory diseases (Olumiant, Taltz, Omvoh), central-nervous-system disorders (Cymbalta, Ebglyss), and migraine (Emgality).
Lilly maintains a robust collaboration network, partnering with Incyte, Boehringer Ingelheim, Roche/Genentech, AbCellera, Verge Genomics, AdvanCell, Chugai, and others to co-develop novel modalities such as targeted-alpha cancer therapies and myeloid-engager platforms for autoimmune disease.
Key financial and sector drivers (FY 2024): revenue of $28.5 bn (+12 % YoY), R&D spend of $6.2 bn (≈22 % of sales), and a 10-year average dividend yield of 2.1 %. The diabetes and obesity markets are expanding at 6-8 % CAGR globally, while oncology pipelines are seeing accelerated FDA approvals, both of which underpin Lilly’s growth outlook.
For a deeper quantitative view of LLY’s valuation dynamics, the ValueRay platform offers a granular, data-driven dashboard worth exploring.
LLY Stock Overview
| Market Cap in USD | 719,702m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1978-01-13 |
LLY Stock Ratings
| Growth Rating | 44.7% |
| Fundamental | 76.0% |
| Dividend Rating | 70.4% |
| Return 12m vs S&P 500 | -22.7% |
| Analyst Rating | 4.24 of 5 |
LLY Dividends
| Dividend Yield 12m | 0.72% |
| Yield on Cost 5y | 4.33% |
| Annual Growth 5y | 15.13% |
| Payout Consistency | 99.5% |
| Payout Ratio | 35.9% |
LLY Growth Ratios
| Growth Correlation 3m | 48% |
| Growth Correlation 12m | -35.1% |
| Growth Correlation 5y | 94.9% |
| CAGR 5y | 33.95% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.98 |
| CAGR/Mean DD 3y (Pain Ratio) | 4.07 |
| Sharpe Ratio 12m | 1.25 |
| Alpha | -21.01 |
| Beta | 0.461 |
| Volatility | 33.64% |
| Current Volume | 2279.7k |
| Average Volume 20d | 3071.7k |
| Stop Loss | 782.7 (-3.2%) |
| Signal | -0.03 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (13.80b TTM) > 0 and > 6% of Revenue (6% = 3.20b TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 4.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.34% (prev 7.92%; Δ 12.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 10.94b <= Net Income 13.80b (YES >=105%, WARN >=100%) |
| Net Debt (36.53b) to EBITDA (19.66b) ratio: 1.86 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (899.8m) change vs 12m ago -0.49% (target <= -2.0% for YES) |
| Gross Margin 82.64% (prev 80.75%; Δ 1.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.64% (prev 54.15%; Δ 7.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.52 (EBITDA TTM 19.66b / Interest Expense TTM 910.1m) >= 6 (WARN >= 3) |
Altman Z'' 2.83
| (A) 0.11 = (Total Current Assets 49.85b - Total Current Liabilities 39.02b) / Total Assets 100.92b |
| (B) 0.17 = Retained Earnings (Balance) 17.38b / Total Assets 100.92b |
| (C) 0.21 = EBIT TTM 17.77b / Avg Total Assets 86.40b |
| (D) 0.17 = Book Value of Equity 14.25b / Total Liabilities 82.57b |
| Total Rating: 2.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.96
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield -0.01% = -0.00 |
| 3. FCF Margin -0.09% = -0.04 |
| 4. Debt/Equity 2.18 = 0.49 |
| 5. Debt/Ebitda 1.86 = 0.28 |
| 6. ROIC - WACC (= 21.54)% = 12.50 |
| 7. RoE 88.36% = 2.50 |
| 8. Rev. Trend 96.50% = 7.24 |
| 9. EPS Trend 39.68% = 1.98 |
What is the price of LLY shares?
Over the past week, the price has changed by -1.27%, over one month by +7.15%, over three months by +6.37% and over the past year by -10.04%.
Is Eli Lilly a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LLY is around 922.19 USD . This means that LLY is currently undervalued and has a potential upside of +14% (Margin of Safety).
Is LLY a buy, sell or hold?
- Strong Buy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the LLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 891 | 10.1% |
| Analysts Target Price | 891 | 10.1% |
| ValueRay Target Price | 1017.5 | 25.8% |
Last update: 2025-10-18 05:03
LLY Fundamental Data Overview
P/E Trailing = 52.3699
P/E Forward = 27.1739
P/S = 13.5135
P/B = 40.2213
P/EG = 0.8974
Beta = 0.461
Revenue TTM = 53.26b USD
EBIT TTM = 17.77b USD
EBITDA TTM = 19.66b USD
Long Term Debt = 34.18b USD (from longTermDebt, last quarter)
Short Term Debt = 5.72b USD (from shortTermDebt, last quarter)
Debt = 39.90b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.53b USD (from netDebt column, last quarter)
Enterprise Value = 756.06b USD (719.70b + Debt 39.90b - CCE 3.55b)
Interest Coverage Ratio = 19.52 (Ebit TTM 17.77b / Interest Expense TTM 910.1m)
FCF Yield = -0.01% (FCF TTM -50.2m / Enterprise Value 756.06b)
FCF Margin = -0.09% (FCF TTM -50.2m / Revenue TTM 53.26b)
Net Margin = 25.91% (Net Income TTM 13.80b / Revenue TTM 53.26b)
Gross Margin = 82.64% ((Revenue TTM 53.26b - Cost of Revenue TTM 9.25b) / Revenue TTM)
Gross Margin QoQ = 84.27% (prev 82.53%)
Tobins Q-Ratio = 7.49 (Enterprise Value 756.06b / Total Assets 100.92b)
Interest Expense / Debt = 0.62% (Interest Expense 249.0m / Debt 39.90b)
Taxrate = 16.47% (1.12b / 6.78b)
NOPAT = 14.84b (EBIT 17.77b * (1 - 16.47%))
Current Ratio = 1.28 (Total Current Assets 49.85b / Total Current Liabilities 39.02b)
Debt / Equity = 2.18 (Debt 39.90b / totalStockholderEquity, last quarter 18.27b)
Debt / EBITDA = 1.86 (Net Debt 36.53b / EBITDA 19.66b)
Debt / FCF = -727.6 (out of range, set to none) (Net Debt 36.53b / FCF TTM -50.2m)
Total Stockholder Equity = 15.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.67% (Net Income 13.80b / Total Assets 100.92b)
RoE = 88.36% (Net Income TTM 13.80b / Total Stockholder Equity 15.62b)
RoCE = 35.68% (EBIT 17.77b / Capital Employed (Equity 15.62b + L.T.Debt 34.18b))
RoIC = 28.87% (NOPAT 14.84b / Invested Capital 51.41b)
WACC = 7.33% (E(719.70b)/V(759.61b) * Re(7.71%) + D(39.90b)/V(759.61b) * Rd(0.62%) * (1-Tc(0.16)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.23%
Fair Price DCF = unknown (Cash Flow -50.2m)
EPS Correlation: 39.68 | EPS CAGR: 52.42% | SUE: 1.48 | # QB: 1
Revenue Correlation: 96.50 | Revenue CAGR: 34.11% | SUE: 1.12 | # QB: 1
Additional Sources for LLY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle